This inventor holds 2 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignee: Boehringer Ingelheim International Gmbh. Active years: 2022-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2025
Title: The Innovations of Dongmei Liu
Introduction
Dongmei Liu is a prominent inventor based in Oxford, CT (US). He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. With a total of 2 patents to his name, Liu's work focuses on innovative solutions for medical challenges.
Latest Patents
Liu's latest patents include groundbreaking inventions such as anti-PD-1 antibodies. This invention relates to new anti-PD-1 (Programmed cell death 1) antibodies and antigen-binding fragments for therapeutic and diagnostic methods. Another notable patent is for anti-Sema3A antibodies, which target semaphorin 3A (Sema3A). This invention outlines methods of using these antibodies for the treatment of various eye or ocular diseases.
Career Highlights
Dongmei Liu is currently associated with Boehringer Ingelheim International GmbH, where he continues to advance his research and development efforts. His work has the potential to impact the treatment of various diseases significantly.
Collaborations
Liu collaborates with talented coworkers, including Priyanka Gupta and Fei Han, who contribute to his innovative projects.
Conclusion
Dongmei Liu's contributions to the field of biotechnology through his patents and collaborations highlight his role as a key inventor in developing therapeutic solutions. His work continues to pave the way for advancements in medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile